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correlated strongly: 0.75 (p < 0.001). The responsiveness was
moderate for SF-6D (SRM = 0.40) and high for EQ-5D
(SRM = 0.83). CONCLUSION: Both SF-6D and EQ-5D cap-
tured worsening and improvements in health over time.
However, the use of EQ-5D resulted in larger utility losses and
gains and in consequence may result in lower cost-utility ratios.
The study showed high responsiveness for EQ-5D and moderate
for SF-6D, indicating that EQ-5D is more suitable for use as
utility measure in clinical trials in elderly hip fracture patients.
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ALLERGY/ASTHMA—Clinical Outcomes Studies
PAA1
SUB-ACUTE LACK OF ASTHMA CONTROL AND
SUBSEQUENT ACUTE ASTHMA EXACERBATIONS: EVIDENCE
FROM MANAGED CARE DATA
Klingman D1, Gutierrez B2, Burudpakdee C1,Wagner S2
1IMS Health, Falls Church,VA, USA, 2AstraZeneca,Wilmington, DE,
USA
OBJECTIVES: To determine whether sub-acute lack of asthma
control (SALAC), independent of current exacerbations, is asso-
ciated with subsequent acute asthma exacerbations. METHODS:
Patients who were aged 12 years as of 2001, continuously
enrolled throughout 2001–2004, and had 1 claims for asthma
(ICD-9-CM code 493.x), no claims for COPD or cystic ﬁbrosis,
and 1 prescriptions for an asthma medication anytime during
2001–2004 were identiﬁed using administrative claims data from
PharMetrics/IMS Health. SALAC was deﬁned as >4 physician
visits for asthma per year (or 2 per quarter) or >5 SABA
prescriptions per year. The impact of asthma control category
during 2001 (exacerbation only, SALAC only, both exacerbation
and SALAC, or neither exacerbation nor SALAC) on having 1
acute asthma exacerbations (hospital admissions, ED visits, or
short-term courses of oral corticosteroid therapy within 7 days of
a physician ofﬁce visit) anytime during 2002–2004 was assessed
using logistic regression. Covariates included gender, age, insur-
ance type, and region. RESULTS: Among 11,779 asthma patients
in 2001, 8% experienced an exacerbation only (EO), 26% expe-
rienced SALAC only (SO), 12% had both an exacerbation and
SALAC (Both), and 54% had neither an exacerbation nor
SALAC (Neither). The 2002–2004 exacerbation rate was higher
in the Both group vs. the EO group (61.8% vs. 55.0%) and in the
SO group vs. the Neither group (37.3% vs. 31.9%). Controlling
for the covariates and compared with the Neither group, the
Both group had a larger impact on the odds of an exacerbation
in 2002–2004 than did the EO group (3.394 [95% CI: 3.009,
3.827] vs. 2.503 [2.176, 2.879], and the SO group had a signiﬁ-
cant and positive effect (1.277 [1.166, 1.399]). CONCLUSION:
SALAC identiﬁes an additional 26% of asthma patients who
have a higher likelihood of a subsequent exacerbation in addition
to the 20% who experienced an exacerbation in 2001.
PAA2
PREVALENCE OF UNCONTROLLED SEVERE PERSISTENT
ASTHMA PATIENTS IN PNEUMOLOGY AND ALLERGY
HOSPITAL UNITS IN SPAIN
Lahoz R1, Picado C2, Plaza V3, Quirce S4, Nadal T5, Casafont J1
1Novartis Pharmaceuticals, Barcelona, Spain, 2Hospital Clínic i
Provincial, Barcelona, Spain, 3Hospital de la Santa Creu i Sant Pau,
Barcelona, Spain, 4Hospital La Paz, Madrid, Spain, 5Trial Form Support,
Barcelona, Spain
OBJECTIVES: Severe persistent asthma is not always adequately
controlled and its prevalence is unknown among pneumology
and allergy hospital units. The aim of this study is to determine
uncontrolled severe persistent asthma prevalence among asth-
matic patients attended in hospital units, to describe their clinical
characteristics and to determine the prevalence of sensibility to
common aeroallergens. METHODS: Cross-sectional epidemio-
logic study conducted in 201 hospital pneumology and allergol-
ogy units in Spain. Asthmatic patients attending these services (in
and out-patients) during a 6-month period were registered.
Demographic data, clinical characteristics, skin-prick test, total
serum IgE, asthma control test (ACQ) and quality of life (AQLQ)
assessments were collected among a sample of asthmatics
patients. RESULTS: A total of 1,423 (3.9% [CI 95%: 3.7–
4.1%]) out of 36,649 asthma patients attending hospital units,
had uncontrolled severe disease, data from 330 was collected.
They showed a poor asthma control (a mean (SD) ACQ score
4.17 [0.96]). 55.9% of the sample had a positive skin-prick test
to common aeroallergens and 53.6% showed high levels of total
serum IgE. The percentage agreement between control assess-
ment by the investigator and by GINA guidelines was moderate
(65.3%, Kappa = 0.365), this discrepancy is basically explained
by an overestimation of control by specialists. CONCLUSION:
1) Uncontrolled severe persistent asthma shows a limited preva-
lence among hospital asthma patients in Spain; 2) The level of the
asthma control is overestimated by physicians; and 3) A half of
the sample fulﬁlled criteria of the allergic disease.
ALLERGY/ASTHMA—Cost Studies
PAA3
A BUDGET IMPACT MODEL FOR DETERMININGTHE COSTS
OF INTRODUCING A NEW EXTRAFINE COMBINATION
(BECLOMETHASONE/FORMOTEROL) FORTHETREATMENT
OF MODERATETO SEVERE PERSISTENT ASTHMA IN SPAIN
Darba J1, Restovic G2
1Universitat de Barcelona, Barcelona, Spain, 2BCN Health Economics
& Outcomes Research, Barcelona, Spain
OBJECTIVES: A budget impact model was developed to esti-
mate the economic impact of introducing beclomethasone/
formoterol extraﬁne for the treatment of moderate to severe
persistent asthma in Spain. METHODS: The analytic model is
based on data from disease prevalence, population growth, drug
consumption, ex-factory prices and market shares forecasting
for Spain. It takes the perspective of the Spanish National Phar-
maceutical budget and time horizon considered is 5 years.
Annual discount rate was set at 5%. Drugs considered in the
study were ﬂuticasone/salmeterol, budesonide/formoterol and
beclomethasone/formoterol extraﬁne. The model estimates the
annual cost to treat patients with moderate to severe persistent
asthma before and after the introduction of beclomethasone/
formoterol extraﬁne in Spain. Annual costs consist of pharma-
cologic treatment costs, laboratory and diagnostic tests costs,
specialist consultation costs and hospitalization costs. All costs
are referred to 2007. RESULTS: It has been estimated that target
population with moderate to severe persistent asthma in Spain
would be around 284,365 in year 2007, arriving at 498,385 in
2012 due to increase in Spanish population and the increase of
asthma prevalence. Total cost for the next 5 years for the treat-
ment of moderate to severe persistent asthma in Spain was
estimated at 1700€ millions before the introduction of
beclomethasone/formoterol extraﬁne and at 1689€ millions after
its introduction. Mean cost per patient was estimated at 642€
before the introduction of beclomethasone/formoterol extraﬁne
and at 637€ after its introduction. CONCLUSION: This budget
impact model estimates that the introduction of beclomethasone/
formoterol extraﬁne for the treatment of moderate to severe
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persistent asthma in Spain is going to represent a savings of 11€
millions in the Spanish National Pharmaceutical budget in the
next 5 years.
PAA4
COST-EFFECTIVENESS ANALYSIS OF OMALIZUMABVS
STANDARDTHERAPY (ST), INTHE MANAGEMENT OF SEVERE
ASHTMA
Martínez M1,Vega G2, Garcia FM3, Rivas R2, Fon F1, Zapata L2
1Novartis, Mexico City, Mexico, 2Guia Mark, Mexico, DF, Mexico,
3IMSS, Mexico DF, Mexico
OBJECTIVES: Omalizumab is a monoclonal antibody indicated
for treatment of severe persistent allergic asthma inadequately
controlled despite an optimal controller therapy. The purpose of
this study is to determine a cost-effectiveness analysis of omali-
zumab vs ST in the treatment of severe asthma in Mexico.
METHODS: A cost-effectiveness analysis was performed based
on a six-state Markov model. The transition probabilities and the
response rate were obtained from a meta-analysis. The pattern of
resource use was derived from the Second Mexican Consensus of
Asthma (steps 4 and 5). Unit costs of resources and medications
were obtained from medical care in IMSS 2004, and were trans-
formed to current prices using inﬂation rates. The cost of oma-
lizumab was provided by the laboratory. The time horizon was
one year. A discount rate was not required. The model was
calibrated. The effectiveness rate was the number of days free
from exacerbations. A one-way and two-way probabilistic sen-
sitivity analysis was used using a Tornado chart. A stochastic
optimization analysis was performed with 500 runs involving
100,000 Monte Carlo iterations; the budget and percent use of
omalizumab were the model restrictions. Maximization of incre-
mental net beneﬁts was obtained with the model. RESULTS: The
expected cost per patient was $14,940 USD ($502) with oma-
lizumab, while this ﬁgure was $6,144 USD ($207) for ST. The
expected effectiveness was 333 (3) and 306 (6) days without
exacerbation/year, respectively. The stochastic optimization
maximized the net incremental beneﬁts with a ratio of 42% for
omalizumab, and 58% for the standard therapy. The sensitivity
analysis was robust in the conclusions of the basic study. CON-
CLUSION: Omalizumab is a cost-effective therapy in the
management of patients with severe asthma. The ratio for oma-
lizumab acquisition with stochastic optimization was 42%.
PAA5
CLINICO-ECONOMICAL ANALYSIS OF USING BUDESONID/
FORMOTEROL INHALER FORTREATMENT OF BRONCHIAL
ASTHMA
Vorobiev P,Avksentieva M, Smirnova M
Moscow Medical Academy named after M.I.Sechenov, Moscow, Russia
OBJECTIVES: To analyze cost-effectiveness of budesonid/
formoterol versus typical practice for treating asthma in Russian
health care system. METHODS: Open, randomized, compara-
tive trial was carried out in 16 cities of Russia. 300 outpatients
were observed during 6 months. A total of 150 from them
were prescribed budesonid/formoterol, 150 continued anti-
inﬂammatory therapy prescribed earlier (typical practice of treat-
ing patients). IN all, 103 patients from them received inhaled
corticosteroids 800–1600 mcg as monotherapy, 21 patient
received inhaled corticosteroids in a combination with long-
acting 2-agonists and 26 patient received cromons. The degree of
restriction of physical activity, frequency of day time and night
attacks were estimated on a scale in 5 points (0-absence of the
infringements, 2–4-moderate and heavy infringements). Applica-
tion of udesonid/formoterol has shown the best results by all
criteria of clinical efﬁciency. RESULTS: The increase of FEV1 by
the end of research (20% on a median) was signiﬁcantly greater
in group of abudesonid/formoterol than in control group (11%).
Cost of treatment (cost of drugs and physician visits) was some-
what higher in budesonid/formoterol group. Average cost-
effectiveness ratio showed that the cost per % increase of FEV1in
group of budesonid/formoterol (484,08 rubles for the 1 month,
1742.68 rubles for 6 months) was lower than in group of com-
parison (1131.56 rubles and 2468.86 rubles). Cost per patient
with absence of moderate or heavy infringements on all used
scales at the end of study also was lower in the ﬁrst group
(9220.54 rubles for the 1 month; 44,684.15 rubles for 6 months)
than in the second group (11,911.13 rubles, 59,037.78 rubles).
CONCLUSION: Budesonid/formoterol is cost-effective in treat-
ment of bronchial asthma.
PAA6
COST EFFECTIVENESS OF BREATH-OPERATED INHALERS IN
UNITED KINGDOM PRIMARY CARE
Haycox A1, Featherstone R2
1University of Liverpool Management School, Liverpool, UK,
2Knowledgeworks Ltd, Saffron Walden, UK
OBJECTIVES: A large scale database analysis was undertaken
comparing resource use in UK primary care patients receiving
inhaled steroids via MDI and BOI. The aim was to compare
resource use over a two-year period of patients receiving inhaled
beclometasone via MDI, with patients utilising BOI.
METHODS: Data was extracted from Din-Link patient-level
databases to compare resource utilisation over 24 months in
patients receiving BOI with those on standard MDI. Entry crite-
ria were: 1) Diagnosis of asthma; 2) Receiving beclometasone via
MDI; and 3) No other preventer medication. Index event was
change to a different MDI or BOI. Key measures included annua-
lised average costs of: i) Primary care consultation for asthma; ii)
Anti-asthma prescriptions; iii) Spacer devices; and iv) Hospital
referral and admissions for asthma. RESULTS: Primary care
medication costs for child patients were 108.62 (BAI) versus
77.23(MDI) and for adults were 79.35 (BAI) versus 92.76
(MDI). Non-medication resource use for child patients over the
period was: GP consultation (63.00 BAI vs 102.68 MDI);
outpatient attendance (18.43 BAI vs 22.62 MDI); hospital
admissions (0.00 BAI vs 15.46 MDI). Non-medication
resource use for adult patients was: GP consultation (82.75
BAI vs 114.20 MDI); outpatient attendance (10.75 BAI vs
12.30 MDI); hospital admissions (28.35 BAI vs 21.39
MDI). Total asthma costs over the two year period for BAI
patients were 190.05 (children) and 201.20 (adults). Com-
parative ﬁgures for MDI patients were 217.99 (children) and
240.56 (adults). CONCLUSION: The additional acquisition
cost associated with BOI appears to be offset by enhanced clinical
effectiveness. A trend in cost effectiveness emerged in favour of
BOI versus the equivalent MDI for both children and adults.
PAA7
A PHARMACOECONOMIC EVALUATION OF SUBLINGUAL
IMMUNOTHERAPY COMPAREDTO SUBCUTANEOUS
IMMUNOTHERAPY INTHETREATMENT OF GRASS POLLEN
INDUCED RHINOCONJUNCTIVITIS
Kristensen FKO, Nyhus K, Merméjean P, Sverre JM
PharmEcon, Asker, Akershus, Norway
OBJECTIVES: For patients with grass pollen induced rhinocon-
junctivitis where immunotherapy is appropriate there are cur-
rently two medically approved treatment alternatives available in
Finland and Norway: Subcutaneous Immunotherapy (SCIT) and
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